![Mika Derynck](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Mika Derynck
Direktor/Vorstandsmitglied bei ENLIVEN THERAPEUTICS, INC.
Vermögen: - $ am 31.05.2024
Aktive Positionen von Mika Derynck
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ENLIVEN THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 23.02.2023 | - |
Independent Dir/Board Member | 23.02.2023 | - | |
Enliven Therapeutics, Inc. /US/
![]() Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | Direktor/Vorstandsmitglied | 19.01.2022 | - |
Amunix Pharmaceuticals, Inc.
![]() Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
Karriereverlauf von Mika Derynck
Ausbildung von Mika Derynck
Boston University | Undergraduate Degree |
Boston University School of Medicine | Doctorate Degree |
Statistik
International
Vereinigte Staaten | 5 |
Israel | 2 |
Operativ
Director/Board Member | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Independent Dir/Board Member | 1 |
Sektoral
Health Technology | 4 |
Consumer Services | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ENLIVEN THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Amunix Pharmaceuticals, Inc.
![]() Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA. | Health Technology |
Enliven Therapeutics, Inc. /US/
![]() Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | Health Technology |
- Börse
- Insiders
- Mika Derynck
- Erfahrung